澳門科技大學
MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY

醫學部
MSD

2026 "Frontiers in Medicine" International Symposium: Future Healthcare in the Era of Science and Technology

2026「探索醫學前沿」國際會議：科技時代的未來健康

2026.04.09

MUST 26 周年校慶系列活動
Anniversary Celebration

Contents / 目錄

Welcome Message

On the occasion of the 26th anniversary of the Macau University of Science and Technology (MUST), it is our great pleasure to welcome you to the 2026 Frontiers in Medicine International Symposium: Future Healthcare in the Era of Science and Technology. We extend our warmest greetings and sincere appreciation to distinguished experts, scholars, industry leaders, and colleagues from around the world for joining us in Macau for this important academic gathering.

Over the past 26 years, MUST has grown steadily into a dynamic and internationally connected university, strategically positioned within the Guangdong–Hong Kong–Macao Greater Bay Area. Guided by a strong commitment to academic excellence and innovation, the University has achieved global recognition, including its placement among the world's top 300 universities in the Times Higher Education rankings. MUST continues to serve as a vital bridge linking the Greater Bay Area with the global academic and research community.

The reorganisation and integration of the Medical Sciences Division in 2022 marked a significant milestone in this journey. By bringing together expertise across pharmacy, traditional Chinese medicine, translational medicine, regenerative medicine, and clinical disciplines, the Division has established a comprehensive innovation ecosystem spanning fundamental research, clinical translation, and real-world application. This integrated framework positions MUST to contribute meaningfully to addressing complex global health challenges.

Anchored in the theme of technology-driven healthcare and innovation-led progress, this symposium provides a high-level platform for cross-disciplinary, cross-regional, and cross-sector dialogue. We look forward to sharing pioneering research, exploring emerging frontiers in medical science and technology, and engaging in thoughtful discussions on challenges and solutions shaping the future of health. Through the exchange of ideas, evidence, and experience, we aim to strengthen the synergy between modern science, clinical practice, and diverse medical traditions.

We hope this gathering in Macau will inspire new perspectives, foster lasting collaborations, and generate meaningful outcomes. We wish all participants a rewarding and productive symposium, and we look forward to advancing together toward a healthier future shaped by science, technology, and collective effort.

Macau University of Science and Technology
April 9, 2026

歡迎辭

濠江論道 共築健康未來

春和景明，濠江煥彩；廿六耕耘，碩果盈枝。值澳門科技大學建校二十六周年校慶之時，2026「探索醫學前沿」國際會議：科技時代的未來健康，如期啟幕。我們謹向遠道而來的各位專家學者、行業翹楚、參會同仁及各界友人，致以最熱烈的歡迎與最誠摯的敬意！

二十六載櫛風沐雨，澳門科技大學立足粵港澳大灣區核心樞紐，以「意誠格物」為訓，深耕學術沃土，勇拓科研新境，成功躋身《泰晤士高等教育》世界大學全球 300 強，成為融通中外、連接灣區與世界的學術高地。2022 年醫學部的整合重組，整合藥學、中醫藥學、轉化醫學、再生醫學、臨床醫學等多學科力量，構建起「基礎研究—臨床轉化—產業應用」的全鏈條創新生態，為應對全球健康挑戰注入強勁動能。

本次會議以「科技賦能健康，創新引領未來」為內核，搭建起跨地域、跨學科、跨領域的高端學術交流平臺。我們期待與各位同仁一道，分享開創性研究成果，探討醫學科技前沿動態，共話健康領域發展瓶頸與破局之道，讓現代科技與傳統醫學交相輝映，讓學術智慧與實踐經驗深度融合，共同書寫科技時代的健康未來。

願此次濠江之聚，成為思想共鳴、合作共贏的紐帶。衷心祝願各位參會順遂、收穫豐沛，在醫學探索的征程上步履不停，攜手為健康事業的進步貢獻力量！

澳門科技大學
2026 年 4 月 9 日

Introduction to the Medical Sciences Division

The Medical Sciences Division (MSD) of the Macau University of Science and Technology (MUST) was established in September 2022 as a dynamic and innovative research and education platform focusing on modern scientific approaches to promote human health. The MSD consists of the Faculty of Chinese Medicine and the Faculty of Medicine with the School of Pharmacy integrated into the Faculty of Medicine, as well as the newly established Macau Institute for Artificial Intelligence in Medicine and Precision Regenerative Medicine Center. The State Key Laboratory of Mechanism and Quality of Chinese Medicine and University Hospital work closely with the Medical Sciences Division and support its development.

The State Key Laboratory of Mechanism and Quality of Chinese Medicine is the first State Key Laboratory in China dedicated to the field of Chinese Medicine. Its research focuses on three main directions: the innovative technologies and methodologies for quality evaluation and mechanistic research of Chinese medicine, innovative drug research and development based on traditional Chinese medicine, as well as precision diagnosis and therapeutic methods for complex diseases. The laboratory currently consists of ten research laboratories and research centers, including the “Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery”, a Nobel laureate workstation.

Chinese Medicine is a treasure in traditional Chinese culture and is becoming an important part of the modern medical system. The Faculty of Chinese Medicine is committed to promoting the development of Chinese Medicine and is supported by the 12th Five-Year Plan of the Chinese government. The Faculty of Chinese Medicine was established in 2000 and offers a complete degree program system, laying a solid foundation for the sustainable development of Chinese Medicine in Macau.

The Faculty of Medicine joined forces with the School of Pharmacy recently to strengthen the basis for pharmaceutical and clinical teaching and research. The Faculty of Medicine offers the only comprehensive Bachelor of Medicine and Bachelor of Surgery (MBBS) course in Macau, aiming to train tomorrow’s doctors who are skilled, confident, and caring. The Faculty also established the Center for Medical Education in Medical Simulation and the Center for Continuing Medical and Health Education to promote professional development and continuing education for medical professionals. The School of Pharmacy at Macau University of Science and Technology was established in 2016. It is the only educational institution that offers both bachelor and doctoral degree in pharmacy authorized by the Macao S.A.R. government providing students with training to understand the comprehensive range of explicit uses of drugs in pharmaceutical research and an opportunity to join in drug discovery and development.

The MSD of MUST is dedicated to promoting innovation, interdisciplinary collaboration, and excellence in research and education to advance the field of medical sciences and improve human health.

醫學部介紹

澳門科技大學（MUST）醫學部（MSD）成立於 2022 年 9 月，是一個富有活力和創新的研究和教育平臺，專注於以現代科學方法促進人類健康。醫學部由中醫藥學院、醫學院（藥學院納入醫學院）、醫學人工智慧所及精準再生醫學中心組成。中藥機制與質量全國重點實驗室及科大醫院將在教學、科研等方面持續助力醫學部的發展。

中藥機制與質量全國重點實驗室是中國第一個致力於中藥領域的國家重點實驗室。其研究集中在三個主要方向：中藥質量評價和機制研究的創新技術和方法、基於傳統中醫藥的創新藥物研發、複雜性疾病的精準診斷和精準治療方法。該實驗室目前由十個研究實驗室和研究中心組成，其中包括由諾貝爾獎得獎者，埃爾文·內爾教授主管的「埃爾文·內爾博士生物物理與創新藥物實驗室」。

中醫是中國傳統文化中的寶藏並逐漸成為現代醫療體系中的重要組成部分。澳門適逢發展中醫藥的最佳契機，國家大力支持澳門發展中醫藥，將其納入國家十三五發展規劃，陸續出台一系列政策支持中醫藥發展。中醫藥學院成立於 2000 年，提供完整的學位課程體系，為澳門中醫藥的可持續發展奠定了堅實的基礎。

醫學院提供澳門唯一的內外全科醫學學士學位課程（MBBS），旨在為澳門培養具有同理心、人文關懷並能提供高效和優質醫療服務的「明日良醫」，醫學院醫學模擬培訓中心和醫療及衛生持續培訓中心，致力開展高質量的本科醫學培訓和持續醫學教育，改善澳門醫療保健服務。藥學院創建於 2016 年，是澳門特區政府唯一認可開辦藥學學士學位課程以及藥學博士學位課程的藥學專門教育機構，促進澳門醫院臨床合理用藥及管理、高水平藥物科學研究、以及醫藥產業發展等各方面的進步。

澳門科技大學醫學部致力於推動創新、跨學科合作、卓越的研究和教育，以推進醫學科學領域的發展，改善人類健康。

Objective of the 2026 “Frontiers in Medicine” International Symposium

- Build a high-level cross-disciplinary platform to share cutting-edge research and explore medical frontiers.
- Integrate modern science and traditional medicine to jointly tackle global health challenges.
- Foster an innovation ecosystem linking basic research, clinical translation and industrial application.
- Gather global experts to promote international cooperation and long-term partnerships.
- Focus on tech-driven healthcare to advance innovation in medical sciences.

2026「探索醫學前沿」國際會議目標

- 搭建跨領域高端平台，分享前沿研究，探索醫學發展方向。
- 融合現代科學與傳統醫學，攜手應對全球健康挑戰。
- 構建基礎研究、臨床轉化與產業應用一體化創新生態。
- 匯聚全球專家，推動國際合作與長期協同發展。
- 聚焦科技賦能醫療，引領醫學科學創新發展。

Abstract

To celebrate the 26th anniversary of the Macau University of Science and Technology (MUST), the 2026 “Frontiers in Medicine” International Symposium is themed ‘Future Healthcare in the Era of Science and Technology’. It brings together preeminent experts, scholars and industry leaders from China, Portugal, Brazil, Ireland and other countries, and is structured into three thematic sessions: Frontiers in Clinical Medicine, Frontiers in Therapeutics, and Frontiers in Molecular Medicine. Specialized lectures are delivered focusing on cutting-edge medical fields including translational medicine, gut microbiota modulation, RNA biology, rare genetic diseases, immune cellular therapy, the disciplinary advantages of traditional Chinese medicine, genome editing, endothelial cell biology, and stroke treatment.

Anchored in the theme of technology-driven healthcare and innovation-led progress, the symposium builds a high-end interdisciplinary academic platform. It facilitates the sharing of pioneering research and exploration of medical frontiers, drives the integration of modern science and traditional medicine, and fosters a full-chain innovation ecosystem of basic research, clinical translation and industrial application. Global experts gather to address global healthcare challenges, deepen international academic cooperation, and inject fresh impetus into the innovative development of medical sciences and the advancement of global healthcare.

摘要

為慶祝澳門科技大學建校 26 周年，本次 2026「探索醫學前沿」國際會議以「科技時代的未來健康」為主題，匯聚來自中國、葡萄牙、巴西、愛爾蘭等多國頂尖專家學者與行業翹楚，設立臨床醫學前沿、前沿治療學、分子醫學前沿三大議題板塊，圍繞轉化醫學、腸道微生物群調控、RNA 生物學、罕見遺傳病、免疫細胞治療、中醫藥學科優勢、基因組編輯、內皮細胞生物學、卒中治療等醫學前沿領域展開專題講座。

會議以「科技賦能健康，創新引領未來」為核心，搭建了跨地域、跨學科、跨領域的高端學術交流平台，不僅促進開創性研究成果的分享與醫學科技前沿動態的探討，更將推動現代科學與傳統醫學的融合，助力構建「基礎研究—臨床轉化—產業應用」全鏈條創新生態。與會專家共同探討全球健康領域發展難題，深化國際學術合作與交流，為解決複雜全球健康挑戰提供新思路，為醫學科學創新發展與全球健康事業進步注入新動能。

Agenda

Meeting venue: R103, R block, Macau University of Science and Technology

Opening Ceremony	
	Welcoming remarks Chair Prof. Paul Kwong-Hang Tam (Vice President of MUST; Member of ASHK)
09:00 – 09:15	**Opening remarks** Dr. Chen Jimin (Member of the National Committee of CPPCC, Vice-Chairman and Secretary General of the University Council of MUST)
	Group photo
2026 "Frontiers in Medicine" International Symposium: Future Healthcare in the Era of Science and Technology	
	Session 1: Frontiers in Clinical Medicine Moderator: Chair Prof. Zhu Yi Zhun (Vice President of MUST; Member of EurASc) ; Prof. Manson Fok (Dean of MUST-FMD)
09:15 – 09:40	**Advances in Translational Medicine and Drug Development** Prof. Chak-sing Lau (The University of Hong Kong)
09:40 – 10:05	**Opportunities for modification of the gut microbiota in rheumatoid arthritis** Prof. João Eurico Cabral da Fonseca (University of Lisbon)
10:05 – 10:30	**RNA and disease: decoding the biology of inherited cardiomyopathies** Prof. Maria do Carmo Fonseca (University of Lisbon)
10:30 – 10:45	Tea Break
10:45 – 11:10	**Treatable rare genetic diseases** Prof. Márcia Gonçalves Ribeiro (Martagão Gesteira Institute of Childcare and Pediatrics, Federal University of Rio de Janeiro)
	Session 2: Frontiers in Therapeutics (1) Moderator: Chair Prof. Jiang Zhi Hong (Vice President of MUST) ; Prof. Zhiguang Sun (Dean of MUST-FC)
11:10 – 11:35	**Current status and challenges in immune cellular therapy** Prof. Sanbing Shen (University of Galway)
11:35 – 12:00	**The Strategic Advantages of Traditional Chinese Medicine and Its Role in Health Promotion** Prof. Qingquan Liu (Beijing Hospital of Traditional Chinese Medicine)
12:00 – 14:30	Lunch Grand Hyatt - Grand Ballroom I

Session 2: Frontiers in Therapeutics (2)
Moderator: Chair Prof. Jiang Zhi Hong (Vice President of MUST) ;
Prof. Zhiguang Sun (Dean of MUST-FC)

14:30 – 14:55	**Hepatic Aquaporins as a Novel Therapeutic Target for Gallstone Disease** Prof. Tonghui Ma (Nanjing University of Chinese Medicine)

Session 3: Frontiers in Molecular Medicine
Moderator: Chair Prof. Paul Kwong-Hang Tam (Vice President of MUST; Member of ASHK) ;
Prof. Xinghua Pan (MUST)

14:55 – 15:20	**Application of RED-CRISPR in genome editing** Prof. Youming Zhang (Shandong University; MAE)
15:20 – 15:45	**Endothelium in health and disease** Prof. Yu Huang (City University of Hong Kong)
15:45 – 16:00	Tea Break
16:00 – 16:25	**From Thrombectomy to Traditional Medicine: A Decade of Clinical Trials Reshaping Acute Ischemic Stroke Treatment** Prof. Wenjie Zi (Second Affiliated Hospital of the Army Medical University (Xinqiao Hospital))
16:25 – 16:50	**Biophysics and Pharmacology of Cardiac KCNQ1 Channels** Asst. Prof. Panpan Hou (2024/2025 Best Research Output Award (Biological and Medical Sciences) of MUST)

日程表

會議地點：澳門科技大學R座R103室

開幕儀式

致歡迎辭
譚廣亨講座教授（澳門科技大學副校長、香港科學院院士）

09:00 – 09:15

致開幕辭
陳季敏博士（全國政協委員、澳門科技大學校董會副主席兼秘書長）

嘉賓和全場大合照

2026「探索醫學前沿」國際會議：科技時代的未來健康

第一部分：臨床醫學前沿

主持人：朱依諄講座教授（澳門科技大學副校長、歐洲科學與藝術學院院士）；
霍文遜教授（澳門科技大學醫學院院長）

09:15 – 09:40	**轉化醫學與藥物研發前沿進展** 劉澤星教授（香港大學）
09:40 – 10:05	**類風濕關節炎中腸道微生物群調控的機遇與實踐** João Eurico Cabral da Fonseca 教授（里斯本大學）
10:05 – 10:30	**RNA與疾病：解碼遺傳性心肌病的生物學機制** Maria do Carmo Fonseca 教授（里斯本大學）
10:30 – 10:45	茶歇
10:45 – 11:10	**可治療的罕見遺傳疾病：治療策略的演進與展望** Márcia Gonçalves Ribeiro 教授（里約熱內盧聯邦大學）

第二部分：前沿治療學 (1)

主持人：姜志宏講座教授（澳門科技大學副校長）；孫志廣教授（澳門科技大學中醫藥學院院長）

11:10 – 11:35	**免疫細胞治療的現狀與挑戰** 沈三兵教授（愛爾蘭高威大學）
11:35 – 12:00	**中醫藥學科優勢與健康** 劉清泉教授（北京中醫醫院）
12:00 – 14:30	午餐 君悅酒店 宴會廳壹

第二部分：前沿治療學 (2)
主持人：姜志宏講座教授（澳門科技大學副校長）；孫志廣教授（澳門科技大學中醫藥學院院長）

14:30 – 14:55	**肝臟水通道蛋白作為膽結石治療新靶點** 麻彤輝教授（南京中醫藥大學）

第三部分：分子醫學前沿
主持人：譚廣亨講座教授（澳門科技大學副校長、香港科學院院士）；
潘星華教授（澳門科技大學）

14:55 – 15:20	**RED-CRISPR聯合應用於基因組編輯** 張友明教授（山東大學、歐洲科學院院士）
15:20 – 15:45	**從健康到疾病** 黃聿教授（香港城市大學）
15:45 – 16:00	茶歇
16:00 – 16:25	**從血栓切除到傳統醫藥：重塑急性缺血性卒中治療的十年臨床試驗之路** 資文杰教授（陸軍軍醫大學第二附屬醫院）
16:25 – 16:50	**心臟KCNQ1通道的工作機制和藥理學研究** 侯盼盼助理教授（澳門科技大學2024/2025科研之星（生物醫學領域））

Advances in Translational Medicine and Drug Development
轉化醫學與藥物研發前沿進展

Professor Chak-sing Lau
劉澤星教授

The University of Hong Kong
香港大學

Professor Lau is the Vice-President & Pro-Vice-Chancellor (Health), Dean of Medicine and Chair and Daniel CK Yu Professor in Rheumatology and Clinical Immunology of the Li Ka Shing Faculty of Medicine at the University of Hong Kong (HKUMed). He is known as a pioneer for establishing and advancing rheumatology in Hong Kong, Asia and beyond.

Prior to his current roles, Professor Lau served as the Assistant Dean in Information Technology and Planning in 2001, and Student Affairs in 2005. In 2010, he was the Director for the Faculty's Bau Institute of Medical and Health Services Education, and in 2013 he took on the role of Associate Dean of Teaching and Learning and was instrumental in reforming the MBBS Curriculum to incorporate a one-year enrichment experience for all medical students. After stepping down from his Associate Deanship in 2018, Professor Lau took up the Chairpersonship of the Department of Medicine and Chairman of the Board of HKUMed from 2019 to 2022. He was also Chief of Service in the Department of Medicine at Hong Kong's Queen Mary Hospital from 2018 to 2022.

Between 2016 and 2020, he presided over the Hong Kong Academy of Medicine, a statutory body for medical and dental specialist training in Hong Kong which is also a key advisory body to the HKSAR Government on health-related policies. Today, he sits on numerous strategic committees/ working groups of Hong Kong's Health Bureau, Hospital Authority and Department of Health. In 2023, he was appointed as a Member of the 14th National Committee of the Chinese People's Political Consultative Conference (CPPCC) representing the health sector, and a general Member of the 14th Beijing Municipal Committee of the CPPCC.

劉澤星教授為風濕病學先驅，致力在本港、亞洲及其他地區建立風濕病學和推動其發展。劉教授現任香港大學副校長（健康）暨李嘉誠醫學院（港大醫學院）第四十一任院長、風濕與臨床免疫學講座教授及于崇光基金教授。

在港大醫學院，劉教授先後於 2001 年擔任助理院長（資訊科技與規劃），並於 2005 年擔任助理院長（學生事務）。10 年，劉教授擔任鮑氏醫學及衛生教育研究所所長，於 2013 年出任副院長（教學），並改革內外全科學士課程，引入全體醫科生為期一年的增潤學年，豐富醫科學生的學習體驗。

2018 年卸任副院長職務後，劉教授於 2019 年至 2022 年擔任港大醫學院內科學系系主任兼醫學院院務委員會主席，同時於 2018 年至 2022 年期間出任瑪麗醫院內科部門主管。2016 年至 2020 年間，劉教授亦曾擔任香港醫學專科學院主席，該機構是本港醫學及牙醫專科培訓的法定機構，亦是香港特別行政區政府在衞生政策上的重要諮詢機構。現時，劉教授是醫務衞生局、醫院管理局及衞生署多個策略委員會及工作小組成員。2023 年，劉教授獲委任為中國人民政治協商會議第十四屆全國委員會醫藥衞生界委員（全國政協委員），及政協北京市第十四屆委員會委員。

Opportunities for modification of the gut microbiota in rheumatoid arthritis
類風濕關節炎中腸道微生物群調控的機遇與實踐

Professor João Eurico Cabral da Fonseca

University of Lisbon
里斯本大學

Professor João Eurico Fonseca is a Full Professor of Medicine/Rheumatology and Dean at the Lisbon School of Medicine, University of Lisbon, and a leading clinician-scientist in the field of rheumatology. He obtained his medical degree in 1992 and completed his PhD in Medicine at the same institution in 2004.

Professor Fonseca currently serves as Head of the Rheumatology Department at ULS Santa Maria and leads the Rheumatology Research Unit, within the Lisbon Academic Medical Center (CAML). His work focuses on the early diagnosis, prognosis and treatment response preview of immune mediated rheumatic diseases.

An internationally recognised authority in rheumatology research, Professor Fonseca has authored more than 450 peer-reviewed scientific publications and has received 46 scientific awards and distinctions. He is a frequent invited speaker at major national and international scientific meetings and contributes extensively to the academic community as a reviewer and editorial board member for several scientific journals.

Professor Fonseca has also supervised numerous undergraduate, master's, doctoral, and postdoctoral researchers, contributing significantly to the training of the next generation of clinician-scientists in rheumatology.

João Eurico Cabral da Fonseca 教授現任里斯本大學醫學院院長，同時擔任內科學 / 風濕病學教授，為該領域頂尖的臨床專家與學術權威。

João Eurico Cabral da Fonseca 教授於 1992 年取得醫學學位，並於 2004 年在同一機構完成醫學博士學位。目前擔任聖瑪麗亞醫院風濕病學科主任，並領導里斯本學術醫學中心（CAML）風濕病學研究單位。他的研究專注於免疫介導性風濕性疾病的早期診斷、預後評估及治療反應預測。

作為國際公認的風濕病學權威，João Eurico Cabral da Fonseca 教授發表逾 450 篇經同行評審的學術論文，並榮獲 46 項科學獎項與殊榮，並應邀於國內外眾多重要學術會議發表演講。他同時擔任多家科學期刊的審稿人及編輯委員會成員，為學術界作出廣泛貢獻。

此外，João Eurico Cabral da Fonseca 教授長期投入教學與人才培育，指導過眾多本科生、碩士生、博士生及博士後研究人員，為培育風濕病學領域的新一代臨床專家與研究人才作出重大貢獻。

RNA and disease: decoding the biology of inherited cardiomyopathies
RNA 與疾病：解碼遺傳性心肌病的生物學機制

Professor Maria do Carmo Fonseca

University of Lisbon
里斯本大學

Professor Maria Carmo-Fonseca is a distinguished molecular biologist and leader in RNA biology. She is Professor at the University of Lisbon Medical School and a Group Leader at the Gulbenkian Institute for Molecular Medicine (GIMM). She co-founded the Institute of Molecular Medicine (iMM) at the University of Lisbon and served as its inaugural Director from 2002 to 2014 before later becoming President. In 2023, iMM merged with the Gulbenkian Institute of Science to create GIMM, where she now serves on the Board of Trustees. She also co-founded GenoMed, a molecular diagnostics spin-off company of iMM.

Professor Carmo-Fonseca is internationally recognized for her pioneering research on RNA biology and gene expression. Her work focuses on understanding how RNA molecules regulate gene expression in health and disease, particularly through mechanisms of transcription and pre-mRNA splicing. Her laboratory has developed innovative approaches to visualize and track single RNA molecules inside living cells, revealing new insights into the kinetics of RNA processing and the dynamic interactions between RNA polymerase II and the spliceosome. More recently, her group has applied these approaches to investigate how defects in co-transcriptional RNA processing contribute to human disease, including genetic cardiomyopathies and hereditary breast cancer.

She was a Visiting Professor at Harvard Medical School and has held numerous prestigious scientific leadership roles, including serving as President of the RNA Society (2021–2022). She is a member of the European Molecular Biology Organization, Academia Europaea, the Portuguese Academy of Sciences, and the Portuguese Academy of Medicine, and serves on the European Research Council Advanced Grants Panel.

Professor Carmo-Fonseca has received numerous major honors recognizing her contributions to science and society, including the Gulbenkian Science Award, the Prémio Pessoa, and the University of Lisbon Prize for her exceptional scientific career and leadership in molecular medicine.

Maria Carmo Fonseca 教授是傑出的分子生物學家，也是 RNA 生物學領域的領軍人物。她現任里斯本大學醫學院教授，並擔任古本基安分子醫學研究所（GIMM）研究組組長。Carmo-Fonseca 教授是里斯本大學分子醫學研究所（iMM）共同創辦人之一，並於 2002 年至 2014 年擔任該所首任所長，其後出任主席。2023 年，iMM 與古本基安科學研究所合併成立 GIMM，她現任該機構理事會成員。此外，她也同時共同創辦了分子診斷衍生公司 GenoMed。

Carmo-Fonseca 教授因其在 RNA 生物學與基因表達領域的開創性研究而享譽國際。其研究聚焦於解析 RNA 分子如何在健康和疾病狀態下調控基因表達，尤其通過轉錄和 pre-mRNA 剪接機制。其實驗室開發了創新技術，可視覺化並追蹤活細胞內的單一 RNA 分子，從而揭示了 RNA 加工動力學以及 RNA 聚合酶 II 與剪接體之間動態相互作用的新見解。近期她的團隊更將此技術應用於探究共轉錄 RNA 加工缺陷如何導致人類疾病，包括遺傳性心肌病與遺傳性乳腺癌。

她曾任哈佛大學醫學院的客座教授，並擔任過多個享有盛譽的科學領導職務，包括 RNA 學會主席（2021–2022）。她是歐洲分子生物學組織、歐洲科學院、葡萄牙科學院以及葡萄牙醫學院的成員，也是歐洲研究理事會高級研究基金評審委員會委員。

Maria Carmo Fonseca 教授因其對科學和社會的卓越貢獻而榮獲多項重要殊榮，包括古本基安科學獎、佩索阿獎以及里斯本大學為表彰其非凡科研成就與分子醫學領導地位所頒發的獎項。

Treatable rare genetic diseases
可治療的罕見遺傳疾病：治療策略的演進與展望

Professor Márcia Gonçalves Ribeiro

Martagão Gesteira Institute of Childcare and Pediatrics,
Federal University of Rio de Janeiro
里約熱內盧聯邦大學

Professor Márcia Ribeiro is a Full Professor in the Department of Pediatrics at the Faculty of Medicine of the Federal University of Rio de Janeiro (UFRJ), Brazil. She obtained her Master's degree in Medicine with a concentration in Pediatrics from UFRJ in 1994 and later completed her PhD in Biological Sciences (Genetics) at the same institution in 2003.

Professor Ribeiro is a senior academic and clinician specializing in pediatrics and medical genetics. She serves as Head of the Medical Genetics Service at the Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG-UFRJ) and is a permanent faculty member of the postgraduate programs in Clinical Medicine at the Faculty of Medicine (UFRJ) and in Maternal and Child Health at IPPMG-UFRJ.

She is a board-certified specialist in Pediatrics (since 1988) through the Brazilian Society of Pediatrics and the Brazilian Medical Association, and in Medical Genetics (since 1995) through the Brazilian Society of Medical Genetics, the Brazilian Medical Association, and the Federal Council of Medicine. Her work focuses on pediatric genetic disorders, translational genetics, and advanced therapies.

Professor Ribeiro has received several competitive research recognitions, including the Young Scientist of Our State Award from Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ) and the Scientist of Our State distinction. She was also awarded a Research Productivity Fellowship (Level 2) from the National Council for Scientific and Technological Development (CNPq). Since 2021, she has served as an expert of the National Network for Advanced Therapies (RENETA), coordinated through the Carlos Chagas Filho Institute of Biophysics at UFRJ in collaboration with Brazilian Health Regulatory Agency (ANVISA) and the United Nations Development Programme.

Through her clinical, academic, and research activities, Professor Ribeiro has contributed significantly to advancing pediatric genetics and translational medicine in Brazil.

Márcia Gonçalves Ribeiro 教授是巴西里約熱內盧聯邦大學（UFRJ）醫學院兒科學系正教授。1994 年於該校取得醫學碩士學位（兒科學領域），2003 年於同校完成生物科學（遺傳學）博士學位。

Ribeiro 教授為資深學者與臨床醫師，專注於兒科學及醫學遺傳學領域。現任里約熱內盧聯邦大學馬爾塔岡・格斯特拉兒科與兒科研究所（IPPMG-UFRJ）醫學遺傳學服務部主任，並為該校醫學院臨床醫學研究所及兒科與兒科研究所婦幼衛生研究所之常任教研人員。她同時擁有巴西兒科學會與巴西醫學協會認證之兒科專科醫師資格（1988 年），以及巴西醫學遺傳學會、巴西醫學協會與聯邦醫學委員會認證之醫學遺傳學專科醫師資格（1995 年）。其研究聚焦於小兒遺傳疾病、轉譯遺傳學及先進療法。

Ribeiro 教授獲多項重要學術獎勵，包括卡洛斯·查加斯·菲略研究支持基金會（FAPERJ）頒發之「本州青年科學家」及「本州傑出科學家」榮銜，並獲國家科技發展委員會（CNPq）授予研究生產力獎學金（第二級）。自 2021 年起，她擔任國家先進療法網絡（RENETA）專家委員，由里約熱內盧聯邦大學卡洛斯・查加斯・菲略生物物理研究所（UFRJ）協調，並與巴西國家衛生監督局（ANVISA）及聯合國開發計劃署合作。

結合臨床、學術與研究，Ribeiro 教授為推動巴西小兒遺傳學與轉譯醫學的發展作出了重大貢獻。

Current status and challenges in immune cellular therapy
免疫細胞治療的現狀與挑戰

Professor Sanbing Shen
沈三兵教授

University of Galway
愛爾蘭高威大學

Professor Sanbing Shen is a Professor and Doctoral Supervisor. He is currently a Professor of Fundamental Stem Cell Biology at the University of Galway, Ireland, where he serves as the Director of the induced Pluripotent Stem Cell (iPSC) Program. He is also the Executive Director of the Confucius Institute of Chinese and Regenerative Medicine. Additionally, he serves as a member of the Expert Advisory Committee of the State Council, China, and was the recipient of the 2021 Dean’s Award for Global Engagement from the University of Galway.

Key Research Achievements: Professor Shen’s primary contributions include the discovery of the VPAC2 receptor as a master switch for the circadian clock and the elucidation of the critical role of the ULK4 gene in brain function. He has established an iPSC biobank containing samples from over 100 individuals. His research has been supported by over €6 million in cumulative funding in the United Kingdom and Ireland. He has published over 100 academic papers with a cumulative total of 18,782 citations. Professor Shen has been a long-term advocate for Ireland-China academic collaboration, leading the establishment of joint research centers and dual-degree programs in TCM and regenerative medicine. Furthermore, he serves as a peer reviewer for more than 30 international journals, including Nature Protocols and PNAS, and is a member of the editorial boards for journals such as Am J Stem Cells and PLOS One.

沈三兵，教授，博士生導師。現任愛爾蘭高威大學基礎幹細胞生物學教授、iPSC 項目主任，以及中醫與再生醫學孔子學院執行院長。同時擔任中國國務院僑辦專家諮詢委員會委員，曾獲 2021 年高威大學全球參與院長獎。

核心科研成就：發現晝夜節律主控開關 VPAC2 受體、揭示 ULK4 基因在腦功能中的關鍵作用，並建立了包含百餘人樣本的 iPSC 生物樣本庫。在英、愛兩國累計獲批科研經費超 600 萬歐元。發表學術論文百餘篇，累計被引用 18,782 次。長期推動中愛高等教育合作，主導建立了多項中醫藥與再生醫學聯合研究中心及雙學位培養項目。此外，擔任 Nature Protocols、PNAS 等 30 餘家國際期刊審稿人，並任 Am J Stem Cells、PLOS One 等學術期刊編委。

The Strategic Advantages of Traditional Chinese Medicine and Its Role in Health Promotion
中醫藥學科優勢與健康

Professor Qingquan Liu
劉清泉教授

Beijing Hospital of Traditional Chinese Medicine
北京中醫醫院

Professor Qingquan Liu is a Professor and Doctoral Supervisor. He currently serves as the President of the Beijing Hospital of Traditional Chinese Medicine (TCM) affiliated to Capital Medical University, Director of the Beijing Institute of TCM, and Director of the Beijing Key Laboratory of Basic Research on Infectious Diseases in TCM. Professor Liu is an esteemed recipient of the "Changjiang (Cheung Kong) Scholar" award from the Ministry of Education and is recognized as a "Qihuang Scholar" by the National Administration of TCM. He is an expert enjoying the Special Government Allowance of the State Council and has been honored as a National Young and Middle-aged Expert with Outstanding Contributions to Health.

His academic leadership roles include Vice President of the Chinese Association of Integrative Medicine, Chairman of the Emergency Branch of the China Association of Chinese Medicine, and President of the Beijing Association of Integrative Medicine. Professor Liu has long been dedicated to the research of TCM in the prevention and treatment of infectious diseases, leading 10 national-level projects—including National Science and Technology Major Projects and key projects of the Ministry of Science and Technology—alongside over 20 provincial and ministerial-level projects. Over the past five years, he has published more than 300 papers, including over 50 SCI-indexed articles. His honors include the First Prize of the Beijing Science and Technology Award, the title of National Advanced Individual in COVID-19 Prevention and Control, and the "Beijing Role Model" award.

劉清泉，教授，博士生導師。現任首都醫科大學附屬北京中醫醫院院長、北京市中醫藥研究所所長，並擔任中醫感染性疾病基礎研究北京市重點實驗室主任。入選教育部「長江學者」、國家中醫藥管理局「岐黃學者」，爲享受政府特殊津貼專家及國家衛生健康突出貢獻中青年專家。兼任中國中西醫結合學會副會長、中華中醫藥學會急診分會主任委員及北京市中西醫結合學會會長等職務。長期致力於中醫藥防治感染性疾病研究，先後承擔國家科技重大專項及科技部重點項目等國家級課題 10 項，省部級課題 20 餘項。近五年發表論文 300 餘篇（其中 SCI 論文 50 餘篇）。曾獲北京市科學技術一等獎、全國衛生健康系統新冠肺炎疫情防控工作先進個人及「北京榜樣」等榮譽稱號。

Hepatic Aquaporins as a Novel Therapeutic Target for Gallstone Disease
肝臟水通道蛋白作為膽結石治療新靶點

Professor Tonghui Ma
麻彤輝教授

Nanjing University of Chinese Medicine
南京中醫藥大學

Professor Ma Tonghui is a Professor and Doctoral Supervisor. He is currently the Dean of the School of Pharmacy at Nanjing University of Chinese Medicine and the Deputy Director of the Key Laboratory of Integrative Acupuncture and Medicine, Ministry of Education. Professor Ma is a recipient of the National Science Fund for Distinguished Young Scholars and a Distinguished Professor of the “Changjiang (Cheung Kong) Scholars Program”. He was also selected for the national level of the “New Century Talents Project” by the Ministry of Personnel and enjoys the Special Government Allowance of the State Council.

His research focuses on the mechanisms of water and salt metabolism and TCM pharmacology. He has led major research initiatives, including a National “973” Program project, a drug discovery grant from the US Cystic Fibrosis Foundation, and numerous industry-partnered projects. To date, Professor Ma has published over 200 research articles with a cumulative total of more than 13,000 academic citations. Since 2015, he has consistently been named on Elsevier’s list of “Highly Cited Chinese Researchers”. His academic contributions have had a significant impact on frontier fields, such as the identification of liver aquaporins as novel therapeutic targets for gallstones.

麻彤輝，教授，博士生導師。現任南京中醫藥大學藥學院院長、針藥結合教育部重點實驗室副主任。獲國家自然科學基金委「國家杰出青年基金」，入選教育部「長江學者獎勵計劃」特聘教授及國家人事部「新世紀百千萬人才工程」國家級人選，享受國務院政府特殊津貼。科研方向聚焦水鹽代謝機制和中藥藥理研究，曾主持國家「973」課題、美國囊性纖維化基金會藥物發現專項基金及多項製藥企業橫向課題。目前發表科研文章 200 餘篇，學術引用累計逾 13,000 次。自 2015 年起連續入選愛思唯爾（Elsevier）高被引中國學者榜單。相關學術成果在肝臟水通道蛋白作爲膽結石治療新靶點等前沿領域具有廣泛影響。

Application of RED-CRISPR in genome editing
RED–CRISPR 聯合應用於基因組編輯

Professor Youming Zhang
張友明教授

Foreign Member of the Chinese Academy of Engineering (CAE)
Member of acatech (Germany)
Member of Academia Europaea
Shandong University
中國工程院外籍院士
德國國家工程院院士
歐洲科學院院士
山東大學

Prof. Zhang has long been engaged in the development and application of DNA/genome editing technologies. He is the original inventor of the revolutionary Red/ET homologous recombination technology and direct DNA cloning, a milestone in genetic engineering. This technology is a fundamental tool for large DNA molecule and genomic modification and is one of the few foundational gene editing technologies with complete intellectual property rights owned by China. It is now widely used by over a thousand research institutions and biopharmaceutical companies worldwide. Prof. Zhang has obtained more than 13 international invention patents and 21 domestic invention patents, and published more than 270 SCI-indexed papers, including 11 in Nature and Nature series journals. The total impact factors of his publications reached more than 1500, Total citations exceed 16000, H-index 61 (from Google Scholar).

張友明教授長期致力於 DNA / 基因組編輯技術的開發與應用研究。他是具有里程碑意義的基因工程技術——Red/ET 同源重組技術與 DNA 直接克隆的原創發明者。該技術是對大分子 DNA 及基因組進行遺傳修飾的基礎工具，也是為數不多的由中國擁有完全自主知識產權的底層基因編輯技術之一。目前，該技術已被全球超過一千家科研機構和生物醫藥公司廣泛應用。張友明教授迄今已獲得 13 項國際發明專利及 21 項國內發明專利，在包括 Nature 及其子刊在內的國際頂級期刊發表 SCI 收錄論文 270 餘篇。其論文總影響因子超過 1500，總引用次數超過 16000 次，h-index 61。

Endothelium in health and disease
從健康到疾病

Professor Yu Huang
黃聿教授

City University of Hong Kong
香港城市大學

Yu HUANG earned his BSc from Fudan University Shanghai Medical College and PhD from University of Cambridge. He was a Chair Professor at Chinese University of Hong Kong (2010–2021) and now holds Jeanie Hu Chair Professorship in Biomedical Sciences at City University of Hong Kong. As a leading vascular biologist, Dr. Huang is the first Chinese scholar to receive both 2024 ISHR Peter Harris Distinguished Scientist Award from the International Society for Heart Research (ISHR) and 2025 Vane Medal from the British Pharmacological Society. He is an elected foreign member of Academia Europaea. He is elected Fellow of ISHR, International Union for Physiological Sciences Academy of Physiology, and British Pharmacological Society. He holds leadership roles in key professional societies as Vice President of Chinese Section of the ISHR and Chinese Association for Physiological Sciences. He is also the first Chinese national to serve as an Associate Editor of Circulation Research. His team aims to elucidate molecular events in endothelial cell dysfunction in hypertension, diabetes, and atherosclerosis. He has co-authored 549 SCI-indexed publications, including papers in Nature, Science, and Circulation Research, with over 39,500 citations and an h-index of 103.

黃聿在復旦大學上海醫學院獲得學士學位，在劍橋大學獲得博士學位。他曾擔任香港中文大學講座教授（2010-2021），現為香港城市大學生物醫學講座教授及胡梁子慧生物醫學教授。黃博士是第一位同時獲得國際心臟研究學會（ISHR）頒發的 2024 年 Peter Harris 傑出科學家獎和英國藥理學會頒發的 2025 年 Vane Medal 的中國藉學者。他於 2025 年當選歐洲科學院外籍院士。他被選為國際心臟研究學會會士、國際生理科學聯合會生理學會會士和英國藥理學會會士。他在多個主要專業學會擔任領導職務，目前仍擔任國際心臟研究學會中國分會副主席和中國生理學會副理事長。他亦是第一位擔任美國心臟協會《循環研究》雜誌副主編的中國藉心血管專家。他團隊的研究主要旨在闡明高血壓、糖尿病和動脈粥樣硬化的內皮細胞功能障礙的分子機制。他已發表 549 篇 SCI 文章，包括發表在《自然》、《科學》和《循環研究》上的論文，被引用次數超過 39,500 次，h 指數為 103。

From Thrombectomy to Traditional Medicine: A Decade of Clinical Trials Reshaping Acute Ischemic Stroke Treatment

從血栓切除到傳統醫藥：重塑急性缺血性卒中治療的十年臨床試驗之路

Professor Wenjie Zi

資文杰教授

Second Affiliated Hospital of the Army Medical University
(Xinqiao Hospital)
陸軍軍醫大學第二附屬醫院

Wenjie Zi, MD, PhD, is a Chief Physician, Doctoral Supervisor, and the Vice Director of the Neurological Medicine Center at the Second Affiliated Hospital of Army Medical University (Xinqiao Hospital). He is a recipient of the prestigious National Science Fund for Distinguished Young Scholars and has been recognized as a Chongqing Outstanding Innovative Leadership Talent. Prof. Zi also holds several key academic leadership roles, including Vice Chairman of the Genetics Branch of the Chinese Stroke Association and Member of the Neurointerventional Committee of the Chinese Medical Doctor Association.

Prof. Zi has dedicated his career to the pathogenesis and therapeutic innovation of acute ischemic stroke. He serves as the principal investigator for over ten major national-level projects, including National Science and Technology Major Projects and grants from the National Natural Science Foundation of China. He has systematically led a series of pivotal multicenter clinical trials, spanning the efficacy validation of endovascular thrombectomy, periprocedural pharmacological optimization, and novel treatment strategies for acute strokes without large vessel occlusion.

An exceptionally prolific researcher, Prof. Zi has published 53 SCI-indexed papers as the first or corresponding author in top-tier international medical journals, including The New England Journal of Medicine (2 papers), JAMA (5 papers), JAMA Neurology, Neurology, and Stroke, accumulating over 2,477 citations. Notably, five of his landmark publications have been highlighted by dedicated editorials in NEJM and JAMA. In recognition of his outstanding contributions to the field, he has been invited to present his research at the International Stroke Conference (ISC) for seven consecutive years.

Prof. Zi's research has profoundly impacted clinical practice, with his findings incorporated into eight domestic and international clinical management guidelines for cerebrovascular diseases. His groundbreaking work has been repeatedly recognized among China's Top 10 Advances in Stroke Prevention and Treatment, China's Top 10 Medical Research, and the Global Top 10 Advances in Cerebrovascular Disease. Furthermore, he is a recipient of the First Prize of the Chongqing Science and Technology Progress Award.

資文杰，醫學博士，主任醫師，博士生導師，現任陸軍軍醫大學第二附屬醫院（新橋醫院）神經醫學中心副主任。國家傑出青年科學基金獲得者，重慶英才創新領軍人才。現兼任中國卒中學會遺傳學分會副主任委員、中國醫師協會神經介入專業委員會委員等學術職務。

資文杰教授長期致力於急性缺血性卒中發病機制及診療創新研究，主持國家科技重大專項、國家自然科學基金等課題十餘項，系統性開展了從血管內血栓切除術療效驗證、圍手術期藥物優化到非大血管閉塞卒中治療的多中心臨床研究。以第一作者／通訊作者在 NEJM（2 篇）、JAMA（5 篇）、JAMA Neurology、Neurology、Stroke 等國際頂級期刊發表 SCI 論著 53 篇，累計被引 2477 次，5 篇論文獲 NEJM、JAMA 等期刊專題評述，連續 7 次受邀於國際卒中大會作大會報告。研究成果寫入國內外腦血管病臨床管理指南 8 項，多次入選中國腦卒中防治十大進展、中國十大醫學研究、全球腦血管病十大進展，獲重慶市科技進步一等獎。

Biophysics and Pharmacology of Cardiac KCNQ1 Channels
心臟KCNQ1通道的工作機制和藥理學研究

Assistant Professor Panpan Hou
侯盼盼助理教授

Macau University of Science and Technology
澳門科技大學

Dr. Panpan Hou received his bachelor’s and doctoral degrees from Huazhong University of Science and Technology. He subsequently underwent postdoctoral training at Washington University in St. Louis, USA, and joined the State Key Laboratory of Quality Research in Chinese Medicine and the Dr. Erwin Neher Laboratory of Biophysics and Innovative Drug Discovery at Macau University of Science and Technology in 2021. Dr. Hou has long been engaged in basic and translational research on ion channels, specifically working mechanisms and regulation of ion channels, the physiological and pathological functions of ion channels, and drug discovery targeting ion channels. He has been published as first/corresponding author in top journals such as Cell Research, Circulation Research, Nature Communications (X2), eLife (X2), PNAS, Pharmacological Research, and others. His research is funded by the National Natural Science Foundation of China, the Joint Project of the Ministry of Science and Technology and the Macao Science and Technology Development Fund, the Macao Science and Technology Development Fund Project, the Macau University of Science and Technology Research Fund, and the American Heart Association Fund. Dr. Hou currently serves as a committee member of the Ion Channels and Receptors Branch of the Chinese Neuroscience Society and the Neurobiophysics Branch of the Chinese Biophysical Society.

侯盼盼博士本科和博士畢業於華中科技大學，後於美國華盛頓大學接受博士後訓練，並於2021年入職澳門科技大學中藥機制與品質全國重點實驗室和埃爾文·內爾博士生物物理與創新藥物實驗室。侯博士長期從事離子通道的基礎和轉化研究，具體包括離子通道的工作機制和調控、離子通道的生理和病理功能、針對離子通道的藥物發現。相關成果以第一/通訊（含共同）作者身份在Cell Research、Circulation Research、Nature Communications（2篇）、eLife（2篇）、PNAS、Pharmacological Research等期刊發表。研究受到國家自然科學基金、國家科技部與澳門科學技術發展基金聯合專案、澳門科學技術發展基金項目、澳門科技大學科研基金及美國心臟學會基金資助。現任中國神經科學學會離子通道與受體分會委員和中國生物物理學會神經生物物理分會委員。

Organizing Committee
籌備委員會

Chairman 主席

Chair Professor Paul Kwong-Hang Tam
譚廣亨講座教授

Vice President, Macau University of Science and Technology

Chairman of Medical Sciences Division Board, Macau University of Science and Technology

Director, Precision Regenerative Medicine Research Centre, Macau University of Science and Technology

Chief Director, Clinical Trials Centre, Macau University of Science and Technology

澳門科技大學副校長

澳門科技大學醫學部委員會主席

澳門科技大學精準再生醫學研究中心總監

澳門科技大學臨床試驗中心首席總監

Coordinator 統籌

Dr. Qian Ding
丁倩博士

Assistant Professor, School of Pharmacy, Macau University of Science and Technology

Assistant Director, Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology

澳門科技大學藥學院助理教授

澳門科技大學天然藥物發現和產業化實驗室助理主任

Committee Members
委員會成員

Chair Professor Jiang Zhi Hong
姜志宏講座教授

Vice President, Macau University of Science and Technology
Director, State Key Laboratory of Mechanism and Quality of Chinese Medicine, Macau University of Science and Technology
Director, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology
澳門科技大學副校長
澳門科技大學中藥機制與質量全國重點實驗室主任
澳門科技大學澳門藥物及健康應用研究院院長

Chair Professor Zhu Yi Zhun
朱依諄講座教授

Vice President, Macau University of Science and Technology
Director, School of Pharmacy, Macau University of Science and Technology
Director, Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology
澳門科技大學副校長
澳門科技大學藥學院院長
澳門科技大學天然藥物發現和產業化實驗室主任

Dr. Chi Wai Chang
曾致慧博士

Director (Development and Clinical), Medical Sciences Division, Macau University of Science and Technology
Vice President & Administrative Director, University Hospital
Executive Director, Clinical Trials Centre, Macau University of Science and Technology
澳門科技大學醫學部總監（發展與臨床）
澳門科大醫院副院長兼行政總監
澳門科技大學臨床試驗中心執行總監

Professor Manson Fok
霍文遜教授

Dean, Faculty of Medicine, Macau University of Science and Technology
President, University Hospital
澳門科技大學醫學院院長
澳門科大醫院院長

Professor Zhiguang Sun
孫志廣教授

Dean, Faculty of Chinese Medicine, Macau University of Science and Technology
澳門科技大學中醫藥學院院長

Dr. Daniel Baptista-Hon
韓守裕博士

Assistant Dean, Faculty of Medicine, Macau University of Science and Technology
澳門科技大學醫學院助理院長

Professor Xinghua Pan
潘星華教授

Professor, Precision Regenerative Medicine Research Centre, Macau University of Science and Technology
澳門科技大學精準再生醫學研究中心教授

Dr. Min Chen
陳敏博士

Associate Professor, Faculty of Chinese Medicine, Macau University of Science and Technology
澳門科技大學中醫藥學院副教授

Administrative Staff
行政人員

Medical Sciences Division / 醫學部

Hok Cheong	張鶴	In Peng Wong	黃彥冰

Faculty of Chinese Medicine / 中醫藥學院

Chunhui Wang	王春輝	Mei Ian Lam	林美欣
Chi Hin Un	袁子軒	Yongyan Lin	林泳言
Chi Han Lou	盧智鵬	Kin Fong Hong	熊建豐
Xia Li	李夏	Pui Man Lei	李佩雯

Faculty of Medicine / 醫學院

Ka Pek Chan	陳家璧	Mei Ian Chim	詹美欣
Flora Rosa Da Conceição	江慧瑩	Lun Yu	于蘭
Sijia Liao	廖斯嘉	Kit Man Ng	吳潔雯
Kin I Chou	曹健怡	Ka Lai Wong	黃家麗
Man Ieng Lao	劉敏瑩		

School of Pharmacy / 藥學院

Shuying Chen	陳書穎	Lok I Wong	黃樂怡
Litao Huang	黃麗陶	Iok Ian Kong	鄺鈺茵
Wei Qi	齊煒	Ka Weng Choi	崔家穎

領航定向
創新啟帆
i.MUST

Enquiries 查詢：

Tel 電話： (853) 8897 3411 / (853) 8897 2341 / (853) 8897 2415 / (853) 8897 2181

Fax 傳真：(853) 2899 0889 **Email 電郵：msd@must.edu.mo**

Address 地址：

Avenida Wai Long NºS 100 - 460, Taipa, Macau, China / 中國澳門氹仔偉龍馬路100-460號

Website 網址: www.must.edu.mo